Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen: doi:10.22028/D291-38231
Titel: Thrombus Aspiration in ThrOmbus containing culpRiT lesions in Non-ST-Elevation Myocardial Infarction (TATORT-NSTEMI): study protocol for a randomized controlled trial
VerfasserIn: de Waha, Suzanne
Eitel, Ingo
Desch, Steffen
Scheller, Bruno
Böhm, Michael
Lauer, Bernward
Gawaz, Meinrad
Geisler, Tobias
Gunkel, Oliver
Bruch, Leonhard
Klein, Norbert
Pfeiffer, Dietrich
Schuler, Gerhard
Zeymer, Uwe
Thiele, Holger
Sprache: Englisch
Titel: Trials
Bandnummer: 14
Seiten: 1-10
Verlag/Plattform: BMC
Erscheinungsjahr: 2013
Freie Schlagwörter: : Non-ST-elevation myocardial infarction
Thrombectomy
Cardiac magnetic resonance imaging
Microvascular obstruction
DDC-Sachgruppe: 610 Medizin, Gesundheit
Dokumenttyp: Journalartikel / Zeitschriftenartikel
Abstract: Current guidelines recommend thrombus aspiration in patients with ST-elevation myocardial infarction (STEMI); however, there are insufficient data to unequivocally support thrombectomy in patients with non-STEMI (NSTEMI).
Methods/Design The TATORT-NSTEMI (Thrombus Aspiration in ThrOmbus containing culpRiT lesions in Non-ST-Elevation Myocardial Infarction) trial is a prospective, controlled, multicenter, randomized, open-label trial enrolling 460 patients. The hypothesis is that, against a background of early revascularization, adjunctive thrombectomy leads to less microvascular obstruction (MO) compared with conventional percutaneous coronary intervention (PCI) alone, as assessed by cardiac magnetic resonance imaging (CMR) in patients with NSTEMI. Patients will be randomized in a 1:1 fashion to one of the two treatment arms. The primary endpoint is the extent of late MO assessed by CMR. Secondary endpoints include early MO, infarct size, and myocardial salvage assessed by CMR as well as enzymatic infarct size and angiographic parameters, such as thrombolysis in myocardial infarction flow post-PCI and myocardial blush grade. Furthermore, clinical endpoints including death, myocardial re-infarction, target vessel revascularization, and new congestive heart failure will be recorded at 6 and 12 months. Safety will be assessed by the incidence of bleeding and stroke.
Summary The TATORT-NSTEMI trial has been designed to test the hypothesis that thrombectomy will improve myocardial perfusion in patients with NSTEMI and relevant thrombus burden in the culprit vessel reperfused by early PCI.
DOI der Erstveröffentlichung: 10.1186/1745-6215-14-110
URL der Erstveröffentlichung: https://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-14-110
Link zu diesem Datensatz: urn:nbn:de:bsz:291--ds-382315
hdl:20.500.11880/34506
http://dx.doi.org/10.22028/D291-38231
ISSN: 1745-6215
Datum des Eintrags: 25-Nov-2022
Fakultät: M - Medizinische Fakultät
Fachrichtung: M - Innere Medizin
Professur: M - Prof. Dr. Michael Böhm
Sammlung:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Dateien zu diesem Datensatz:
Datei Beschreibung GrößeFormat 
1745-6215-14-110.pdf507,55 kBAdobe PDFÖffnen/Anzeigen


Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons Creative Commons